Prenetics Global Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sheng Wu Yeung
- Full Time Employees
- 98
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Unit 701-706, K11 Atelier King’s Road Quarry Bay Hong Kong
- IPO Date
- Jul 16, 2021
- CIK
- 0001876431
- Website
- prenetics.com
- Similar Companies
- Business
- Prenetics Global Limited (NASDAQ:PRE) is a health sciences company focused on advancing consumer and clinical health through genomics, diagnostics, wellness products, and a pioneering Bitcoin treasury strategy. Founded in 2014 and headquartered in Quarry Bay, Hong Kong, the company operates primarily in Hong Kong, the United States, and internationally, targeting consumers, athletes, and patients seeking preventive care, early disease detection, and personalized wellness. Its core offerings include premium health and wellness supplements under the flagship IM8 brand, co-founded with David Beckham; consumer genetic testing via CircleDNA, which employs next-generation sequencing for comprehensive health, wellness, and predisposition insights; precision oncology diagnostics such as ACTOnco for solid tumor treatment guidance and ACTHRD for homologous recombination deficiency assessment through its ACT Genomics unit; fulfillment and distribution of sports nutrition products under the Europa brand; and multi-cancer early detection technologies via the Insighta joint venture with Prof. Dennis Lo. In recent developments, Prenetics completed a $44 million oversubscribed equity offering in October 2025 from strategic investors including Kraken, Exodus (NYSE:EXOD), XtalPi, DL Holdings, Jihan Wu's GPTX, and Aryna Sabalenka, bolstering its $120 million liquidity position with zero debt; subsequently acquired 100 Bitcoin as the initial deployment toward a dual-engine health-and-Bitcoin accumulation strategy, reaching 378 BTC valued at approximately $46 million; reported record third-quarter 2025 results with IM8 on track for $120 million annual recurring revenue; initiated a strategic review of non-core assets including Europa Sports Partners, CircleDNA, and Insighta to focus capital on high-growth IM8; and saw key executives complete open-market share purchases totaling $1.45 million in November 2025, signaling strong internal confidence in long-term value creation.
Prenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF)
VINFAST LAUNCHES CERTIFIED PRE-OWNED PROGRAM, OFFERING PREMIUM ELECTRIC VEHICLES WITH INDUSTRY-LEADING 10-YEAR TRANSFERABLE WARRANTY
CELEBRITY RIVER CRUISES INNOVATES PRE- AND POST-CRUISE EXPERIENCES WITH LAUNCH OF BEFORE AND AFTER STAYS IN FOUR EUROPEAN CITIES
BIRKENSTOCK PRE Stabilization Notice
Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue
MEXC SPACEX(PRE) Launchpad Subscriptions Exceed $173M Across Two Phases
Prenetics Appoints Hudson Leogrande, Founder and CEO of Multi-Billion-Dollar DTC Brand Comfrt, to Board of Directors as IM8 Accelerates TikTok and Meta Expansion
MEXC SPACEX(PRE) Phase 2 Launchpad: 30% Off Subscription and Extra Airdrops for Stock Trading
BNP PARIBAS PRESENTS THE GROWTH STRATEGY OF ITS COMMERCIAL BANK IN BELGIUM (CPBB) AND RAISES ITS PROFITABILITY TARGETS TO 22% PRE-TAX RONE IN 2028 AND 25% IN 2030
MEXC SPACEX(PRE) Launchpad Subscriptions Surpass $56 million, with the Offering Oversubscribed by Up to 15.5x
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
Prenetics Global Q1 Earnings Call Highlights
Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M
Prenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call
Prenetics' IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
INTEGRA RECEIVES FINAL APPROVAL OF EXPLORATION PLAN OF OPERATIONS FOR THE WILDCAT DEPOSIT, ADVANCING NEVADA NORTH PROJECT TOWARD PRE-FEASIBILITY STUDY
Prenetics Global: Quarterly Subscription Focus Could Turn $120M AAR Into A Billion-Dollar Machine
Prenetics Global: On Course To Hit Profitability Amid Globalization Drive
Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS)